Improved arthropathy scores after use of Extended Half-Life (EHL) products in prophylactic treatment of adult patients with Haemophilia A & B

被引：0
|
作者：
Christidi, Styliani-Despoina [1 ]
Thevaeos, George [1 ]
Zannou, Anna [2 ,3 ]
Vlahopoulou, Dimitra [2 ,3 ]
Veziris, George [1 ]
Gavalaki, Maria [2 ,3 ]
Kourampa, Anna [2 ,3 ]
机构：
[1] Laikon Gen Hosp, Dept Orthoped, Athens, Greece
[2] Blood Transfus Ctr, Athens, Greece
[3] Natl Reference Ctr Congenital Bleeding Disorders, Athens, Greece
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
Haemophilia; Extended Half-Life (EHL); HJHS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-WE-040
引用
收藏
页码：38 / 39
页数：2
相关论文
共 50 条
  • [31] Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors
    Klamroth, Robert
    Kragh, Nana
    Arnaud, Alix
    Guyot, Patricia
    Wilson, Amanda
    Wojciechowski, Piotr
    Wdowiak, Marlena
    Margas, Wojciech
    Bystricka, Linda
    Tosetto, Alberto
    ADVANCES IN THERAPY, 2025, 42 (01) : 427 - 441
  • [32] Real World Analysis of Coagulation Factor IX Utilization and Costs in Hemophilia B Patients Switching From Standard Half-Life To Extended Half-Life Products
    Tortella, B. J.
    Fogarty, P. F.
    Alvir, J.
    Mcdonald, M.
    Spurden, D.
    Pleil, A. M.
    HAEMOPHILIA, 2017, 23 : 41 - 42
  • [33] Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia
    Versloot, Olav
    Iserman, Emma
    Chelle, Pierre
    Germini, Federico
    Edginton, Andrea N.
    Schutgens, Roger E. G.
    Iorio, Alfonso
    Fischer, Kathelijn
    HEMASPHERE, 2022, 6 (04): : E694
  • [34] EXTENDED HALF-LIFE COAGULATION FACTOR IX IN HAEMOPHILIA B PROPHYLAXIS: A COST-EFFECTIVENESS ANALYSIS
    Iannazzo, S.
    Cortesi, P. A.
    Myren, K.
    Eldar-Lissai, A.
    Mantovani, L. G.
    VALUE IN HEALTH, 2016, 19 (07) : A587 - A587
  • [35] Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres
    Malec, Lynn M.
    Croteau, Stacy E.
    Callaghan, Michael U.
    Sidonio, Robert F., Jr.
    HAEMOPHILIA, 2020, 26 (03) : E128 - E129
  • [36] Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria
    Ay, Cihan
    Feistritzer, Clemens
    Rettl, Joachim
    Schuster, Gerhard
    Vavrovsky, Anna
    Perschy, Leonard
    Pabinger, Ingrid
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [37] Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria
    Cihan Ay
    Clemens Feistritzer
    Joachim Rettl
    Gerhard Schuster
    Anna Vavrovsky
    Leonard Perschy
    Ingrid Pabinger
    Scientific Reports, 11
  • [38] REAL WORLD FACTOR DISPENSATION AND EXPENDITURES IN US PATIENTS WITH HEMOPHILIA B: STANDARD HALF-LIFE VS. EXTENDED HALF-LIFE FACTOR IX REPLACEMENT PRODUCTS
    Chhabra, A.
    Spurden, D.
    Tortella, B. J.
    Fogarty, P. F.
    Pleil, A.
    Rubinstein, E.
    Alvir, J.
    VALUE IN HEALTH, 2018, 21 : S111 - S111
  • [39] Real World Data Analysis of Coagulation Factor IX Costs in Specific Patients with Hemophilia B Switching from Standard Half-Life to Extended Half-Life Products
    Tortella, Bartholomew J.
    Fogarty, Patrick F.
    Alvir, Jose
    McDonald, Margaret
    Spurden, Dean
    Pleil, Andreas M.
    BLOOD, 2016, 128 (22)
  • [40] Regional variation and cost implications of prescribed extended half-life factor concentrates among US Haemophilia Treatment Centres for patients with moderate and severe haemophilia
    Croteau, Stacy E.
    Cheng, Dunlei
    Cohen, Alice J.
    Holmes, Chris E.
    Malec, Lynn M.
    Silvey, Michael
    Thornburg, Courtney D.
    Wheeler, Allison P.
    Kouides, Peter A.
    Raffini, Leslie J.
    Neufeld, Ellis J.
    HAEMOPHILIA, 2019, 25 (04) : 668 - 675
12345